396 related articles for article (PubMed ID: 29215763)
1. Breast cancer: The translation of big genomic data to cancer precision medicine.
Low SK; Zembutsu H; Nakamura Y
Cancer Sci; 2018 Mar; 109(3):497-506. PubMed ID: 29215763
[TBL] [Abstract][Full Text] [Related]
2. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
3. Clinical target sequencing for precision medicine of breast cancer.
Tsuchida J; Rothman J; McDonald KA; Nagahashi M; Takabe K; Wakai T
Int J Clin Oncol; 2019 Feb; 24(2):131-140. PubMed ID: 30604156
[TBL] [Abstract][Full Text] [Related]
4. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
[TBL] [Abstract][Full Text] [Related]
5. Germline mutations in lung cancer.
Shukuya T; Takahashi K
Respir Investig; 2019 May; 57(3):201-206. PubMed ID: 30639082
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer.
Ross JS; Gay LM
Pathology; 2017 Feb; 49(2):120-132. PubMed ID: 28034454
[TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
8. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
[TBL] [Abstract][Full Text] [Related]
9. The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics.
Chan HT; Chin YM; Low SK
Oncol Ther; 2019 Jun; 7(1):1-32. PubMed ID: 32700193
[TBL] [Abstract][Full Text] [Related]
10. Precancer Atlas to Drive Precision Prevention Trials.
Spira A; Yurgelun MB; Alexandrov L; Rao A; Bejar R; Polyak K; Giannakis M; Shilatifard A; Finn OJ; Dhodapkar M; Kay NE; Braggio E; Vilar E; Mazzilli SA; Rebbeck TR; Garber JE; Velculescu VE; Disis ML; Wallace DC; Lippman SM
Cancer Res; 2017 Apr; 77(7):1510-1541. PubMed ID: 28373404
[TBL] [Abstract][Full Text] [Related]
11. Impact of germline and somatic missense variations on drug binding sites.
Yan C; Pattabiraman N; Goecks J; Lam P; Nayak A; Pan Y; Torcivia-Rodriguez J; Voskanian A; Wan Q; Mazumder R
Pharmacogenomics J; 2017 Mar; 17(2):128-136. PubMed ID: 26810135
[TBL] [Abstract][Full Text] [Related]
12. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
Rasnic R; Brandes N; Zuk O; Linial M
BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
[TBL] [Abstract][Full Text] [Related]
13. Personalized genomic analyses for cancer mutation discovery and interpretation.
Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
[TBL] [Abstract][Full Text] [Related]
14. Genomic medicine and risk prediction across the disease spectrum.
Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
[TBL] [Abstract][Full Text] [Related]
15. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
[TBL] [Abstract][Full Text] [Related]
16. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers.
Federici G; Soddu S
J Exp Clin Cancer Res; 2020 Mar; 39(1):46. PubMed ID: 32127026
[TBL] [Abstract][Full Text] [Related]
17. Making Sense of Genetic Information: The Promising Evolution of Clinical Stratification and Precision Oncology Using Machine Learning.
Baptiste M; Moinuddeen SS; Soliz CL; Ehsan H; Kaneko G
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065872
[TBL] [Abstract][Full Text] [Related]
18. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
19. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia.
Pui CH; Nichols KE; Yang JJ
Nat Rev Clin Oncol; 2019 Apr; 16(4):227-240. PubMed ID: 30546053
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.
Stover DG; Wagle N
Curr Oncol Rep; 2015 Apr; 17(4):15. PubMed ID: 25708799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
